Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
| Autor: | Varnado OJ; Eli Lilly and Company, Indianapolis, IN, USA., Vu M; Optum Life Sciences, HEOR, Eden Prairie, MN, USA., Buysman EK; Optum Life Sciences, HEOR, Eden Prairie, MN, USA., Kim G; Eli Lilly and Company, Indianapolis, IN, USA., Allenback G; Optum Life Sciences, HEOR, Eden Prairie, MN, USA., Hoyt M; Eli Lilly and Company, Indianapolis, IN, USA., Trenz H; Optum Life Sciences, HEOR, Eden Prairie, MN, USA., Cao F; Optum Life Sciences, HEOR, Eden Prairie, MN, USA., Viktrup L; Eli Lilly and Company, Indianapolis, IN, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current medical research and opinion [Curr Med Res Opin] 2024 Apr; Vol. 40 (4), pp. 635-646. Date of Electronic Publication: 2024 Feb 22. |
| DOI: | 10.1080/03007995.2024.2316864 |
| Abstrakt: | Objective: To describe long-term (24-month) treatment patterns of patients initiating galcanezumab versus standard of care (SOC) preventive migraine treatments including anticonvulsants, beta-blockers, antidepressants, and onabotulinumtoxinA using administrative claims data. Methods: This retrospective cohort study, which used Optum de-identified Market Clarity data, included adults with migraine with ≥1 claim for galcanezumab or SOC preventive migraine therapy (September 1, 2018 - March 31, 2020) and continuous database enrollment for 12 months before (baseline) and 24 months after (follow-up) the index date (date of first claim). Baseline patient demographics, clinical characteristics, and treatment patterns were analyzed after 24-month follow-up, including adherence (measured as the proportion of days covered [PDC]), persistence, discontinuation (≥60-day gap), restart, and treatment switch. Propensity score matching (1:1) was used to balance the galcanezumab and SOC cohorts. Results: The study included 2307 matched patient pairs with 24-month follow-up. The mean age across cohorts was 44.5 years (females: ∼87%). Patients in the galcanezumab versus SOC cohort demonstrated greater treatment adherence (PDC: 48% vs. 38%), with more patients considered adherent (PDC ≥80%: 26.6% vs. 20.7%) and persistent (322.1 vs. 236.4 d) (all p < .001). After 24-month follow-up, fewer galcanezumab-treated patients had discontinued compared with SOC-treated patients (80.1% vs. 84.7%; p < .001), of which 41.3% and 39.6% switched to a non-index medication, respectively. The most prevalent medication patients switched to in both cohorts was erenumab. Significantly greater proportions of patients who initiated galcanezumab versus SOC medications switched to fremanezumab ( p < .001) and onabotulinumtoxinA ( p = .016). Conclusion: Patients who initiated galcanezumab for migraine prevention had higher treatment adherence and persistence compared with those who initiated SOC medications after 24-month follow-up. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|